港股异动 | 微创心通-B(02160)盘中涨超9% 微创心通TAVI核心产品在摩洛哥获批上市

智通财经2025-12-29

智通财经APP获悉，微创心通-B(02160)盘中涨超9%，截至发稿，涨6.06%，报1.05港元，成交额448.37万港元。消息面上，微创心通的VitaFlow Liberty/自由·维心流经导管主动脉瓣及可回收系统，摩洛哥获批上市，标志着该产品首次进入非洲市场。摩洛哥医疗器械市场对进口产品依赖度高，此次获批为该产品后续拓展非洲其他国家奠定基础。值得注意的是，12月19日，微创医疗宣布心通收购...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2595204296?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-12-29 14:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2595204296","market":"us","top_or_hot":-1,"title":"港股异动 | 微创心通-B(02160)盘中涨超9% 微创心通TAVI核心产品在摩洛哥获批上市","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，微创心通-B(02160)盘中涨超9%，截至发稿，涨6.06%，报1.05港元，成交额448.37万港元。消息面上，微创心通的VitaFlow Liberty/自由·维心流经导管主动脉瓣及可回收系统，摩洛哥获批上市，标志着该产品首次进入非洲市场。摩洛哥医疗器械市场对进口产品依赖度高，此次获批为该产品后续拓展非洲其他国家奠定基础。值得注意的是，12月19日，微创医疗宣布心通收购...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1386432.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>港股异动 | 微创心通-B(02160)盘中涨超9% 微创心通TAVI核心产品在摩洛哥获批上市</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n港股异动 | 微创心通-B(02160)盘中涨超9% 微创心通TAVI核心产品在摩洛哥获批上市\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-12-29 14:22 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1386432.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，微创心通-B(02160)盘中涨超9%，截至发稿，涨6.06%，报1.05港元，成交额448.37万港元。消息面上，微创心通的VitaFlow Liberty/自由·维心流经导管主动脉瓣及可回收系统，摩洛哥获批上市，标志着该产品首次进入非洲市场。摩洛哥医疗器械市场对进口产品依赖度高，此次获批为该产品后续拓展非洲其他国家奠定基础。值得注意的是，12月19日，微创医疗宣布心通收购...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1386432.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1574","symbol_name":"生物医药B类股","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1386432.html","article_id":"2595204296","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2595204296","pubTimestamp":1766989357,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，微创心通-B(02160)盘中涨超9%，截至发稿，涨6.06%，报1.05港元，成交额448.37万港元。消息面上，微创心通的VitaFlow Liberty/自由·维心流经导管主动脉瓣及可回收系统，摩洛哥获批上市，标志着该产品首次进入非洲市场。摩洛哥医疗器械市场对进口产品依赖度高，此次获批为该产品后续拓展非洲其他国家奠定基础。值得注意的是，12月19日，微创医疗宣布心通收购心律的合并落地。此次并购将推动微创医疗旗下结构性心脏病与心律管理两大核心业务板块的深度整合。随着最新整合方案的公布，意味着微创医疗将加速构建覆盖心力衰竭全病因、全阶段、全过程的综合器械管理方案。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1574":"生物医药B类股","02160":"微创心通-B","TAVI":"Tavia Acquisition Corp","BK1583":"高瓴概念","BK1100":"医疗保健设备"},"translate_title":"Changes in Hong Kong stocks | MicroPort CardioFlow-B (02160) rose more than 9% during the session MicroPort CardioFlow TAVI core product was approved for listing in Morocco","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02160":1.5,"TAVI":1.5},"content_text":"智通财经APP获悉，微创心通-B(02160)盘中涨超9%，截至发稿，涨6.06%，报1.05港元，成交额448.37万港元。消息面上，微创心通的VitaFlow Liberty/自由·维心流经导管主动脉瓣及可回收系统，摩洛哥获批上市，标志着该产品首次进入非洲市场。摩洛哥医疗器械市场对进口产品依赖度高，此次获批为该产品后续拓展非洲其他国家奠定基础。值得注意的是，12月19日，微创医疗宣布心通收购心律的合并落地。此次并购将推动微创医疗旗下结构性心脏病与心律管理两大核心业务板块的深度整合。随着最新整合方案的公布，意味着微创医疗将加速构建覆盖心力衰竭全病因、全阶段、全过程的综合器械管理方案。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2595204296","isCrawlerRequest":true}